RESULTS: Adjunct colesevelam had significantly greater LDL-C-lowering effect than niacin alone (placebo); -20.67% vs -12.86%, respectively (P = .0088). Niacin-mediated increases
in FPG were significantly less with adjunct colesevelam (1.8 mg/dL vs 6.7 mg/dL; P = .0046), and fewer colesevelam subjects had increases of >= 10 mg/dL in FPG (8 vs 17, respectively). HKI 272 Adjunct colesevelam resulted in significantly smaller increases in hemoglobin A(1c) than placebo (0.06% vs 0.18%, respectively; P = .005). Consistent with hemoglobin A(1c) and FPG changes, fructosamine levels significantly decreased with colesevelam treatment (-5.0 mu mol/L) but increased with placebo (3.0 mu mol/L; P =.0255).
CONCLUSIONS: Colesevelam
as an adjunct to niacin therapy further lowers LDL-C while obviating the adverse effects of niacin on glucose metabolism in patients with dyslipidemia and IFG. (c) 2013 National Lipid Association. All rights reserved.”
“BACKGROUND: The Philadelphia Department of Public Health Tuberculosis (TB) Control Program has a progressively severe, stepwise legal process for managing non-adherent TB patients, potentially culminating in incarceration.
OBJECTIVE: CB-839 mw To review the application of legal procedures and to evaluate their effectiveness in the management of non-adherent TB patients.
METHODS: We evaluated this process by reviewing patients’ records from 2001 to 2005 to identify all non-adherent patients and determine their treatment outcomes.
RESULTS: In this period, we initiated
the legal process for 39 non-adherent patients. One patient died, and nine patients were lost. Twenty-nine patients became adherent after the use of a legal intervention. Our final completion percentage VX-689 in vivo was 76.3%.
CONCLUSION: Our legal process improved the treatment completion rate for patients who would otherwise have been non-adherent. Increasing treatment completion rates reduce the risk of relapse and disease transmission as well as the growing rate of anti-tuberculosis drug resistance.”
“Complement component 9 (C9) deficiency is relatively common, especially in Japan. Here we present the case of a 27-year-old Japanese woman whose obstetric history involved three mid-trimester miscarriages (at 22 weeks’, 18 weeks’ and 21 weeks’ gestation) and one early spontaneous miscarriage. Her fifth pregnancy was successfully managed by cervical cerclage at 13 weeks’ gestation, followed by clindamycin administration (600 mg/day for 7 days) and progesterone injections (250 mg/week). She gave birth to a healthy 3326-g male infant at 40 weeks and 1 day gestation after natural onset of labor. After delivery, the serum complement components were analyzed. C9 protein and activity were undetectable in the patient’s serum.